Kaida Biopharma’s chair and acting CEO discusses how President Trump’s MFN policies and other regulatory actions are impacting pharma’s ability to invest in new treatments and adjusting international launch strategies.
Dr. Stella Vnook
Advertisement
Dr. Stella Vnook is chair and acting CEO of Kaida BioPharma.
Articles by Dr. Stella Vnook
Dr. Stella Vnook explains how pharma pricing is likely to be impacted by various regulatory actions, such as MFN.
Dr. Stella Vnook explains how US pricing regulations, such as MFN and the IRA, are forcing pharma companies to adjust strategies in international markets.
Dr. Stella Vnook discusses how pricing transparency and VBC might have a more positive impact than MFN and other pricing regulations.
Advertisement
Latest Updated Articles
The United State's Regulatory Impact on Global Drug LaunchesApril 27th 2026
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote
2
Global Disruptions to the Pharma Supply Chain: Q&A with Jeff Golfman
3
FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers
4
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
5